A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis
Sponsor: Celgene
Listed as NCT03324503, this NA trial focuses on Sarcoidosis, Pulmonary and remains completed. Sponsored by Celgene, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Mar 2020 — Jan 2021 [monthly]
Completed NA
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Jul 2019 — Mar 2020 [monthly]
Recruiting NA
-
Jun 2018 — Jul 2019 [monthly]
Recruiting NA
-
May 2018 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting · Phase: PHASE1 → NA
-
Nov 2017 — May 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
For direct contact, visit the study record on ClinicalTrials.gov .